中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (2): 136-138.doi: 10.35541/cjd.20200982

• 论著 • 上一篇    下一篇

利格列汀相关的BP230型大疱性类天疱疮一例国内首报

万立1，2    刘美娜1，2    陈金波2    陈柳青2   

  1. 1江汉大学医学院，武汉  430056；2武汉市第一医院皮肤科  430022
  • 收稿日期:2020-10-10 修回日期:2020-12-18 发布日期:2021-01-29
  • 通讯作者: 陈金波；陈柳青 E-mail:chen999jb@163.com; chlq35@126.com
  • 基金资助:
    国家自然科学基金（81101190）；米尔斯坦亚美医学基金会皮肤病研究项目基金（MMAAP，2018年）；江汉大学科研创新基金项目（YKYCXJJYX18001）

Anti-BP230-type bullous pemphigoid associated with linagliptin treatment: first case report in China

Wan Li1,2, Liu Meina1,2, Chen Jinbo2, Chen Liuqing2   

  1. 1School of Medicine, Jianghan University, Wuhan 430056, China; 2Department of Dermatology, Wuhan No.1 Hospital, Wuhan 430022, China
  • Received:2020-10-10 Revised:2020-12-18 Published:2021-01-29
  • Contact: Chen Jinbo; Chen Liuqing E-mail:chen999jb@163.com; chlq35@126.com
  • Supported by:
    National Natural Science Foundation of China （81101190）; Milstein Medical Asian American Partnership Foundation Research Project Award in Dermatology （MMAAP, 2018）; Research Innovation Fund Project of JiangHan University （YKYCXJJYX18001）

PDF

34

摘要： 【摘要】 患者女，66岁，因头皮、颈部水疱1个月就诊。既往有2型糖尿病病史6年，于起疹前6个月开始口服二肽基肽酶4抑制剂利格列汀5 mg每日1次。皮肤科检查：头皮散在绿豆至花生米大小水疱，部分水疱破溃，可见渗出、结痂；左侧颈部一鸽蛋大小大疱及2个绿豆大小水疱，疱壁紧张，疱液清亮，基底无明显红斑，尼氏征阴性。酶联免疫吸附试验示抗BP180 NC16A抗体5.81 kU/L、抗BP230抗体139.76 kU/L。颈部皮损组织病理检查示表皮下水疱形成，疱内中性粒细胞及少许嗜酸性粒细胞浸润。诊断：BP230型局限型大疱性类天疱疮。该例二肽基肽酶4抑制剂相关的BP230型大疱性类天疱疮为国内首次报道。

关键词: 类天疱疮, 大疱性, 二肽基肽酶Ⅳ抑制剂, 抗BP230抗体

Abstract: 【Abstract】 A 66-year-old female patient presented with blisters on the scalp and neck for 1 month. She had a history of type 2 diabetes for 6 years, and started taking the dipeptidyl peptidase-4 inhibitor linagliptin at a dose of 5 mg once a day 6 months before the onset of eruption. Skin examination showed scattered mung bean- to peanut-sized blisters on the scalp, and some blisters broke with exudation and crusts. There was a pigeon egg-sized bulla and two mung bean-sized blisters on the left neck, with tense blister walls, clear blister fluids, non-erythematous base, and Nikolsky′s sign was negative. Enzyme-linked immunosorbent assay revealed that the serum levels of anti-BP180 NC16A and anti-BP230 antibodies were 5.81 and 139.76 kU/L respectively. Histopathological examination of the blister on the neck showed subepidermal blister formation, and infiltration with neutrophils and a few eosinophils in the blister. The patient was finally diagnosed with localized anti-BP230-type bullous pemphigoid. This case of anti-BP230-type bullous pemphigoid associated with the dipeptidyl peptidase-4 inhibitor linagliptin was firstly reported in China.

Key words: Pemphigoid, bullous, Dipeptidyl-peptidase Ⅳ inhibitors, Anti-BP230 antibody